Skip to contentP
Panacea Life Sciences Holdings, Inc.
P
PLSHPanacea Life Sciences Holdings, Inc. Q3 2023 · 10-Q
Revenue$347.85K$347.85K−5.0% vs Q3 2022 Net Income-$2.15M-$2.15MN/M vs Q3 2022 EPS Diluted-$0.13-$0.13N/M vs Q3 2022 Gross Profit$146,619+209.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Panacea Life Sciences Holdings, Inc. · CIK 1552189 · Engraved from SEC EDGAR
Operating Cash Flowderived-$728,869N/M Margins · derivedGross margin42.1%+29.2 pt vs Q3 2022
Operating margin-406.5%−27.3 pt vs Q3 2022
Net margin-618.4%+117.2 pt vs Q3 2022
ended Sep 30, 2023 · filed Nov 14, 2023 · 45 d after period end